Therapeutic Approach for IDH2-Mutated AML
Case: A 65-Year-Old Woman withIDH2-Mutated AML
November 2017
May 2018
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More